Unknown Author
4 min
This systematic review and meta-analysis aimed to compare the clinical efficacy and safety of oral dexamethasone versus oral prednisone for treating acute asthma exacerbations in children. The authors searched multiple databases (PubMed, Embase, Scopus, CENTRAL, and Google Scholar) for randomized controlled trials (RCTs) and quasi-RCTs published up to August 2019. The primary outcome was the relapse rate (defined as an unscheduled visit to the ED or clinic), while secondary outcomes included hospital readmission and the incidence of vomiting.
The analysis included seven studies involving pediatric patients. The pooled results indicated no statistically significant difference in relapse rates between dexamethasone and prednisone, regardless of whether the follow-up period was 1–5 days or 10–15 days. Similarly, there was no significant difference in hospital readmission rates between the two treatments. However, a notable clinical advantage was found regarding adverse effects: patients treated with dexamethasone experienced significantly less vomiting both in the emergency department and at home compared to those treated with prednisone.
For clinicians, the choice between dexamethasone and prednisone often hinges on patient compliance and side-effect profiles. Prednisone is frequently associated with a bitter taste and higher rates of vomiting, which can lead to treatment non-adherence and subsequent relapse. This study suggests that dexamethasone is a viable, potentially better-tolerated alternative that maintains similar clinical efficacy. However, the authors emphasize that due to the small sample sizes and heterogeneity of existing trials, further large-scale, high-quality RCTs are required to provide more definitive evidence.
Alex: So medically, they're equivalent at the core job?
Sam: That's what the data suggests. But there was a meaningful difference in side effects. Children taking prednisone were significantly more likely to vomit—both while still at the hospital and after going home.
Alex: That's a real practical problem. If the medicine is that unpleasant, it's much harder for parents to make sure the child actually finishes the full course.
Sam: Exactly. And that's the underlying logic here. It's not that dexamethasone is a stronger drug—it's that a shorter, more tolerable course is more likely to be completed. A medicine that stays down is more effective than a medicine that doesn't, regardless of what it says on the label.
Alex: So the clinical decision is really about whether the patient can realistically finish the treatment, not just about the drug's raw pharmacological power?
Sam: That's the key takeaway. Even across children with varying levels of asthma severity, the pattern held: dexamethasone was consistently easier to tolerate. Think of it as a sprint versus a marathon. The dexamethasone course is short and intense. Prednisone is a longer haul, and for a young child with a bitter-tasting medicine, that's a meaningful obstacle.
Alex: You mentioned this was a meta-analysis. Did the researchers flag any limitations?
Sam: They did, and it's worth noting. For some outcomes—like hospital readmission rates—the individual studies simply didn't include enough participants to draw firm conclusions. The finding on vomiting is well-supported, but the evidence for some other outcomes is more limited. That's a reminder that even a well-designed meta-analysis can only be as strong as the studies it draws from.
Alex: So the honest summary is: dexamethasone appears to work just as well, with meaningfully fewer side effects, but there are still questions that need larger studies to answer properly?
Sam: That's a fair characterisation. The evidence points toward dexamethasone as the more practical choice for children, but clinicians should weigh the full picture rather than treating this as a settled question across every possible outcome.
Alex: It's a useful reminder that in medicine, how a treatment fits into a patient's real life matters just as much as how it performs in theory. Thanks for listening to ResearchPod.